RT Journal Article
T1 Safety and immediate humoral response of COVID-19 vaccines in chronic kidney disease patients: the SENCOVAC study.
A1 Quiroga, Borja
A1 Soler, María José
A1 Ortiz, Alberto
A1 Martínez Vaquera, Shaira
A1 Jarava Mantecón, Carlos Jesús
A1 Useche, Gustavo
A1 Sánchez Márquez, María Gabriela
A1 Carnerero, Manuel
A1 Jaldo Rodríguez, María Teresa
A1 Muñoz Ramos, Patricia
A1 Ruiz San Millán, Juan Carlos
A1 Toapanta, Nestor
A1 Gracia-Iguacel, Carolina
A1 Aguilar Cervera, María Cinta
A1 Balibrea Lara, Noelia
A1 Leyva, Alba
A1 Rojas, José
A1 Gansevoort, Ron T
A1 de Sequera, Patricia
A1 SENCOVAC Collaborative Network, 
K1 COVID-19
K1 SARS-CoV-2
K1 antibodies
K1 humoral response
K1 vaccine
AB Chronic kidney disease (CKD) patients are at high-risk for severe coronavirus disease 2019 (COVID-19). The multicentric, observational and prospective SENCOVAC study aims to describe the humoral response and safety of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines in CKD patients. Safety and immediate humoral response results are reported here. Four cohorts of patients were included: kidney transplant (KT) recipients, and haemodialysis (HD), peritoneal dialysis (PD) and non-dialysis CKD patients from 50 Spanish centres. Adverse events after vaccine doses were recorded. At baseline and on Day 28 after the last vaccine dose, anti-Spike antibodies were measured and compared between cohorts. Factors associated with development of anti-Spike antibodies were analysed. A total of 1746 participants were recruited: 1116 HD, 171 PD, 176 non-dialysis CKD patients and 283 KT recipients. Most patients (98%) received mRNA vaccines. At least one vaccine reaction developed after the first dose in 763 (53.5%) and after the second dose in 741 (54.5%) of patients. Anti-Spike antibodies were measured in the first 301 patients. At 28 days, 95% of patients had developed antibodies: 79% of KT, 98% of HD, 99% of PD and 100% of non-dialysis CKD patients (P  The rate of anti-Spike antibody development after vaccination in KT patients was low but in other CKD patients it approached 100%, suggesting that KT patients require persistent isolation measures and booster doses of a COVID-19 vaccine. Potential differences between COVID-19 vaccines should be explored in prospective controlled studies.
YR 2022
FD 2022
LK http://hdl.handle.net/10668/19817
UL http://hdl.handle.net/10668/19817
LA en
DS RISalud
RD Apr 6, 2025